Drug Development Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X

Most Read

  1. EMA issues positive opinion on biomarker for Parkinson’s trials
  2. New drugs and therapeutic options help the immune system fight cancer
  3. May’s top news stories
  4. US biosimilar setbacks highlight difficulty of cost-effective development
  5. POINT trial may increase clopidogrel use in secondary ischemic stroke prevention

Latest Content

Quick and Flexible Elemental Screening with Omnian

Omnian was developed for Malvern Panalytical's high-end x-ray fluorescence (XRD) spectrometer and is also available for the Epsilon 4 energy dispersive x-ray fluorescence (EDXRF) benchtop systems. This powerful combination brings together the strengths of Omnian with the ease-of-use of Epsilon 4.

Talzenna (talazoparib)

Talzenna (talazoparib) for the Treatment of Advanced Breast Cancer

Talzenna™ (talazoparib) is an inhibitor of the poly adenosine diphosphate (ADP) ribose polymerase (PARP) enzyme that is indicated for the treatment of human epidermal growth factor receptor 2 (HER2) negative breast cancer in adult patients with the BRCA-mutated (gBRCAm) gene.

Latest News

Read our magazine

Pharma Technology Focus is the essential reading material for decision-makers in the pharmaceutical industry, bringing you the latest news and analysis in an exciting, interactive format.

Send me notifications of new editions:

Go Top